Back

Long-term improvement in myocardial structure and function in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with acoramidis compared with a natural history cohort

28 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Cardiac magnetic resonance of amyloidosis and myocardial remodelling Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Awais Sheikh

National Amyloidosis Centre, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Left ventricular remodelling index: Reference ranges and prognostic associations in 44,000 UK Biobank participants
Doctor R. Roy (London, GB)
Abstract Slides Video
Presentation thumbnail
Proteome-wide mendelian randomization identifies circulating proteins influencing cardiac structure and function
Doctor R. Roy (London, GB)
Abstract Slides Video
Presentation thumbnail
Longitudinal changes in amyloid burden as measured by extracellular volume (ECV) on cardiac MRI for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)
Doctor M. O'Neill-Dee (Boston, US)
Abstract Slides Video
Presentation thumbnail
Characteristics and clinical significance of myocardial work in cardiac light-chain amyloidosis: pressure-volume loop analysis based on cardiac magnetic resonance
Doctor S. Liang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Cardiometabolic myocardial remodelling across the glycaemic spectrum: a multi-level meta-analysis of CMR T1 mapping and extracellular volume
Doctor A. Dharan (Melbourne, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac magnetic resonance of amyloidosis and myocardial remodelling

The Event

Event poster

ESC Congress 2026

28 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of acoramidis on all-cause mortality, cardiovascular hospitalization and NT-proBNP in variant ATTR-CM - results from ATTRibute-CM
18 May 2025
thumbnail
Congress Presentation
A biopsy-based pilot clinical study: monitoring the effectiveness of tafamidis treatment of patients with transthyretin amyloid cardiomyopathy.
25 August 2023
thumbnail
Congress Presentation
Imaging-guided risk stratification in transthyretin amyloidosis
28 August 2026
thumbnail
Congress Presentation
Improvements in cardiac functional status and health-related quality of life in patients receiving early access tafamidis
9 May 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources